Biomarin Pharmaceutical Inc. · NASDAQ:BMRN
Biomarin Pharmaceutical — Merger or Acquisition (December 2025)
12 slides from Biomarin Pharmaceutical's merger presentation, Dec 19, 2025
Slide 1: BioMarin to Acquire Amicus Therapeutics
BioMarin to Acquire Amicus Therapeutics • Expands BioMarin’s position as a leader in rare diseases • Creates value from Day 1 December 19, 2025
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation and the associated conference call and webcast contain forward-looking statements about, among other things, the proposed acquisition of Amicus Therapeutics (Amicus) by BioMarin Pharmaceutical Inc. (BioMarin) and the business prospects of Amicus and BioMar
Slide 3: Agenda
Agenda • BioMarin and Amicus: An Ideal Fit • Overview of Financial Terms • Expansion and Diversification of BioMarin’s Core Enzyme Business • Reaching More Patients Globally who can Benefit from Innovative Therapies Q&A with BioMarin Team: Alexander Hardy Brian Mueller Cristin Hubbard Greg Friberg C
Slide 4: A Strategic Fit that Accelerates BioMarin's Growth Trajectory
A Strategic Fit that Accelerates BioMarin’s Growth Trajectory Shared Focus on Rare Accelerates & Substantially Accretive Disease Diversifies Revenue Beginning in 2027 • Shared commitment to prioritize • Adds two marketed, high-growth • Expected to be accretive to Non- finding and treating patients w
Slide 5: Attractive Transaction Terms and Leverage Profile
Attractive Transaction Terms and Leverage Profile Purchase Price Funding & Capital Impact Approvals & Timing $14.50 per share $4.8B Equity Value BOD Approved BioMarin has entered into a Transaction to be financed through Transaction has been unanimously definitive agreement to acquire a combination
Slide 6: Two New Therapies Expected to Accelerate and Diversify Revenues
Two New Therapies Expected to Accelerate and Diversify Revenues Accelerates Total BioMarin Expands and Diversifies BioMarin’s Revenues Revenue Streams Illustrative $2.8B 2025 Q3 YTD Actuals BioMarin BioMarin Enzyme Therapies VOXZOGO Other 2025 2030 6
Slide 7: Products and Indications Fit Seamlessly into BioMarin's Enzyme Therapies Portfolio
Products and Indications Fit Seamlessly into BioMarin’s Enzyme Therapies Portfolio • Fabry disease: A rare disease caused by mutation • Late-onset Pompe Disease (LOPD): Rare, in galactosidase alpha gene (GLA) and deficiency of inherited genetic disorder caused by mutation in GAA α-Gal A enzyme. With
Slide 8: Galafold is the First and Only Oral Therapy for Fabry Disease
Galafold is the First and Only Oral Therapy for Fabry Disease for Fabry Disease Annual Revenue ($M) • Strong strategic fit within BioMarin’s Enzyme +10-15%1 Therapies business unit FY’25 • Approved in more than 40 countries, including the U.S., EU, UK, and Japan $458 • Opportunity to deepen reach in
Slide 9: Pending U.S. Galafold Intellectual Property Litigation Resolved
Pending U.S. Galafold Intellectual Property Litigation Resolved All Pending U.S. Galafold IP Litigation Resolved • Amicus entered into license agreements with Aurobindo and Lupin for Galafold 123mg capsules • Amicus will grant Aurobindo and Lupin licenses to market generic versions of Galafold in th
Slide 10: Pombiliti + Opfolda is the Only Two-Component Therapy for the Treatment of Pompe Disease
Pombiliti + Opfolda is the Only Two-Component Therapy for the Treatment of Pompe Disease for Pompe Disease Annual Revenue ($M) • Reimbursed in 15 countries with 10 countries +50-65%1 added in 2025, opening access to ~2,400 people FY’25 with Pompe • Approved in adults with LOPD • Potential label expa
Slide 11: Transforming BioMarin For The Next Phase of Growth
Transforming BioMarin For The Next Phase of Growth Expands BioMarin’s position as a leader in rare diseases with addition of two, high-growth products with numerous expansion opportunities, including geographies, age label, indications Opportunity to find and treat more patients with Fabry disease a
Slide 12: IOMARIN
IOMARIN B
BioMarin Pharmaceutical — Merger or Acquisition (December 2025) on 6ix